This class of biologic may work particularly well in blood cancers with mutated nucleophosmin 1 (NPM1). The antibody may be combined with a delta opioid receptor (DOR) inhibitor and/or a menin ...

Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, is approaching a critical juncture in its development ...

Review articles cover how pre-MEASURE has impacted clinical decision-making and the interpretation of NPM1 MRD throughout the treatment course of AML. Other manuscripts address the limitations of ...